A ground­break­ing can­cer drug nabs fast OK, giv­ing Eli Lil­ly boast­ing rights as a ri­val speeds close be­hind

5 years ago
R&D
FDA+

Covid-19 roundup: Charles Riv­er gets slammed by the pan­dem­ic; For­mer Sanofi R&D chief Elias Zer­houni heads a list of ...

6 years ago
Coronavirus

A new play­er en­ters the KRAS game with Fortress; Gilead picks up once-failed can­cer drug from Molo­gen's fire sale

6 years ago
News Briefing

Ovid's lead drug shows promis­ing ef­fi­ca­cy sig­nal in Frag­ile X syn­drome study, but op­ti­mal dos­ing reg­i­men is un­clear ...

6 years ago
R&D

Fresh off pos­i­tive Nu­plazid da­ta, Aca­dia adds new clin­i­cal drug from Van­der­bilt in mile­stone-heavy deal

6 years ago
Deals

Amid lab space scarci­ty, a life sci­ences com­plex to rise in South San Fran­cis­co hub

6 years ago
Deals
R&D

Ex-As­traZeneca ex­ec Kris­ten Buck hops aboard Icon as CMO; Im­muno­core taps Bri­an Di­Do­na­to as CFO

6 years ago
Peer Review

More than 1,000 clin­i­cal tri­als were stopped by the pan­dem­ic — in­clud­ing dozens in PhI­II

6 years ago
Bioregnum
R&D

Covid-19 roundup: Can­cer drug re­search takes a big hit, sur­vey finds; Chaot­ic remde­sivir dis­tri­b­u­tion con­tin­ues to ...

6 years ago
R&D
Coronavirus

FDA is­n't lift­ing the clin­i­cal hold on Sol­id Bio's Duchenne MD gene ther­a­py just yet — but is there a sil­ver ...

6 years ago
Cell/Gene Tx
FDA+

Or­chard Ther­a­peu­tics prunes jobs to re­fo­cus pri­or­i­ties on big­ger fruit

6 years ago
R&D

Two years af­ter a wrench­ing set­back, Pro­tag­o­nist touts a slice of da­ta and sets sights on piv­otal tri­al in a ...

6 years ago
R&D

'Deeply com­mit­ted' Jim Wil­son pours more of his life's work in­to Pas­sage Bio — lock­ing in more gene ther­a­py ...

6 years ago
Deals
Cell/Gene Tx

CDER re­leas­es pol­i­cy for han­dling new­ly iden­ti­fied safe­ty sig­nals

6 years ago
FDA+

Macro­Gen­ics CEO Scott Koenig gets the pre-AS­CO par­ty start­ed with some en­cour­ag­ing pipeline tid­bits — leav­ing lots ...

6 years ago
Bioregnum
R&D

Blood test for can­cer de­tec­tion com­pa­ny Grail rakes in $390M in lat­est round

6 years ago
Financing
Startups

Covid-19 roundup: Mod­er­na adds vac­cine ex­perts as PhI­II tri­al looms; Feng Zhang group snags in­stant OK on ...

6 years ago
Coronavirus

Step­ping on Bio­Mar­in's turf, PTC Ther­a­peu­tics picks up PKU drug for a song

6 years ago
Deals

Flag­ship-backed Evelo Bio­sciences joins Covid-19 hunt with pro­pos­al for bac­te­ria tri­al

6 years ago
R&D
Coronavirus

Tetraphase has two suit­ors, de­spite strug­gling mar­ket for an­tibi­otics

6 years ago
Deals

No­var­tis lands cap­ma­tinib ap­proval, giv­ing them a sec­ond po­ten­tial block­buster from In­cyte

6 years ago
Pharma
FDA+

As­traZeneca's block­buster Farx­i­ga se­cures land­mark ap­proval in heart fail­ure pa­tients, re­gard­less of whether they ...

6 years ago
R&D
FDA+

An­oth­er sparse round of NASH da­ta; TG rais­es $60M af­ter PhI­II suc­cess

6 years ago
News Briefing

J&J R&D ex­ec Na­jat Khan — and da­ta sci­ence — are get­ting an el­e­vat­ed role at the phar­ma gi­ant

6 years ago
People
R&D
First page Previous page 829830831832833834835 Next page Last page
A service from the Financial Times